Primary aldosteronism: Diagnostic and therapeutic considerations

Current Cardiology Reports

Volumn 7, Issue 6, 2005, Pages 412-417

  Nishizaka, Mari K ^b   Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROCHLOROTHIAZIDE; POTASSIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ACUTE KIDNEY FAILURE; ADRENAL CORTEX ADENOMA; ALDOSTERONE BLOOD LEVEL; CARDIOVASCULAR RISK; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; PLASMA RENIN ACTIVITY; POPULATION DISTRIBUTION; PREVALENCE; PRIMARY HYPERALDOSTERONISM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 28244444860     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-005-0058-7     Document Type: Review

References (23)

1. Conn JW: Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955, 45:6-17.
2. Fishman LM, Kuchel O, Tucker R, et al.: Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 to 1975. Mayo Clin Proc 1977, 52:549-555.
3. Gordon RD, Ziesak MD, Tunney TJ, et al.: Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trail volunteers. Clin Exp Pharmacol Physiol 1993, 20:296-298.
4. Gordon RD, Stowasser M, Tunny TJ, et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315-318.
5. Fardella CE, Mosso L, Gómez-Sánchez C, et al.: Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000, 85:1863-1867.
6. Rayner BL, Opie LH, Davidson JS: The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000, 90:394-400.
7. Lim PO, Dow E, Brennan G, et al.: High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000, 14:311-315.
8. Rayner BL, Myers JE, Opie LH, et al.: Screening for primary aldosteronism-normal ranges for aldosterone and renin in three South African population groups. S Afr Med J 2001, 91:594-599.
9. Lim PO, Rodgers P, Cardale K, et al.: Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999, 353:40.
10. Loh K-C, Koay ES, Khaw M-C, et al.: Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000, 85:2854-2859.
11. Schwartz GL, Turner ST: Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005, 51:386-394.
12. Mosso L, Carvajal C, González A, et al.: Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161-165.
13. Conn JW, Cohen EL, Rovneer DR, et al.: Normokalemic primary aldosteronism. A detectable cause of curable "essential" hypertension. JAMA 1965, 193:200-206.
14. Calhoun DA, Nishizaka MK, Zaman MA, et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
15. Gallay BJ, Ahmad S, Xu L, et al.: Screening for primary aldosteronism without discontinuing hypertensive mediations: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699-705.
16. Eide IK, Torjesen PA, Drolsum A, et al.: Low-renin status in therapy-resistant hypertension: a due to efficient treatment. J Hypertens 2004, 22:2217-2226.
17. Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al.: Validity of plasma aldosterone-to-renin activity ration in African American and white subjects with resistant hypertension. Am J Hypertens 2005, 18:805-812.
18. Streeten DHP, Tomycz N, Anderson GH: Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 1979, 67:403-413.
19. Holland OB, Brown H, Kuhnert L, et al.: Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984, 6:717-723.
20. Nishizaka MA, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
21. Gordon RD, Stowasser M, Rutherford JC: Primary aldosteronism: are we diagnosing and operating on too few patients? World J Surg 2001, 25:941-947.
22. Engeli S, Böhnke J, Gorzelniak K, et al.: Weight loss and the rennin-angiotensin-aldosterone system. Hypertension 2005, 45:356-362.
23. Calhoun DA, Nishizaka MK, Zaman MA, et al.: Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004, 125:112-117.